Medicine and Dentistry
AL Amyloidosis
31%
Amyloid Cardiomyopathy
63%
Amyloidosis
32%
Atherosclerosis
6%
ATTR Amyloidosis
45%
Biological Marker
6%
Biological Phenomena and Functions Concerning the Entire Organism
6%
Bone Scintigraphy
31%
Carbon 11
14%
Cardiomyopathy
11%
Cardiovascular Disease
31%
Cardiovascular System
31%
Diagnostic Accuracy
6%
Diagnostic Performance
31%
Disease Activity
6%
Disease Exacerbation
9%
Echocardiography
6%
Florbetaben (18F)
31%
Fluorine-18
11%
Health Outcomes
6%
Heart Muscle Ischemia
6%
Heart Muscle Perfusion
6%
Immunoglobulin Light Chain
31%
Liver Biopsy
5%
Molecular Imaging
63%
New York Heart Association Class
12%
Nuclear Medicine
31%
Patisiran
12%
Personalized Medicine
31%
Positron Emission Tomography
75%
Positron Emission Tomography
14%
Radioactive Tracer
24%
Radiopharmaceutical Agent
6%
Retrospective Cohort Study
6%
Scintigraphy
15%
Sensitivity and Specificity
5%
Serum Amyloid P
15%
Silencer Gene
6%
Single-Photon Emission Computed Tomography
12%
Systematic Review
63%
Technetium-99
31%
Transient Elastography
5%
Transthyretin
100%
Treatment Response
15%
Troponin T
6%
Vascular Disease
6%
Keyphrases
AL Amyloidosis
19%
ATTR Amyloidosis
63%
ATTRv
31%
Body Ratio
15%
Bone Scintigraphy
31%
Cardiac Biomarkers
14%
Cardiac Involvement
35%
Cardiomyopathy
16%
Consensus Criteria
11%
Diagnostic Performance
31%
Diastolic Parameters
7%
Disease Progression
7%
Dynamic Quantification
7%
Early Follow-up
31%
Early Markers
7%
Echocardiography
7%
Florbetaben
31%
Gene Variants
18%
Hereditary Transthyretin
14%
High-sensitivity Cardiac Troponin
31%
Immunoglobulin Light Chains
31%
Infiltrative Cardiomyopathy
7%
Light Chain Amyloidosis
31%
Liver Involvement
31%
Liver Stiffness
31%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
18%
Nuclear Imaging
31%
Nuclear Molecular Imaging
31%
NYHA Class
15%
Patisiran
15%
Positron Emission Tomography
31%
Potential Treatments
7%
Quantitative Biomarkers
7%
Regret
31%
Retrospective Cohort Study
7%
Scintigraphy
11%
Serum Amyloid A
11%
Silencer
7%
Specific Response
7%
Technetium-99m
31%
Thickness Parameter
7%
Tracer Uptake
15%
Transthyretin Amyloid Cardiomyopathy
31%
Transthyretin Amyloidosis
31%
Transthyretin Gene
26%
Transthyretin Stabilizers
23%
Treatment Response
7%
Troponin
7%
Wall Thickness
7%
Whole-body
15%
Pharmacology, Toxicology and Pharmaceutical Science
Amyloid
31%
Amyloidosis
21%
Atherosclerosis
6%
ATTR Amyloidosis
45%
Biological Marker
6%
Carbon 11
14%
Cardiomyopathy
37%
Cardiovascular Disease
31%
Cohort Study
6%
Disease Activity
6%
Disease Exacerbation
9%
Florbetaben
31%
Fluorine 18
11%
Ischemia
6%
Patisiran
12%
Radiopharmaceutical Agent
6%
Technetium 99m
31%
Tracer
24%
Transthyretin
63%
Troponin T
6%
Vascular Disease
6%
